Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2011 Apr;13(2):348-51.
doi: 10.1007/s11307-010-0369-y.

Influence of glioma's multidrug resistance phenotype on (99m)Tc-tetrofosmin uptake

Affiliations

Influence of glioma's multidrug resistance phenotype on (99m)Tc-tetrofosmin uptake

George A Alexiou et al. Mol Imaging Biol. 2011 Apr.

Abstract

Purpose: Multidrug resistance (MDR) remains a major obstacle to successful chemotherapeutic treatment of cancer. Several chemotherapeutic and radiopharmaceutical agents are substrates of the pumps encoded by the MDR genes, and therefore, their accumulation is prevented. We evaluated in vivo whether [(99m)Tc]tetrofosmin ((99m)Tc-TF) uptake is influenced by the MDR profile of gliomas.

Procedures: Eighteen patients with histologically confirmed glioma were included in the study. Brain single-photon emission computed tomography by (99m)Tc-TF was performed within a week prior to surgical excision, and the expression of MRP5 was assessed by immunohistochemistry. Radiotracer accumulation was assessed by a semiquantitative method, calculating the lesion-to-normal uptake ratio.

Results: Using Spearman's ρ analysis, we found no correlation between tracer uptake expressed as lesion-to-normal and MRP5 expression. There was a significant correlation between glioma aggressiveness as assessed by Ki-67/MIB-1 and MRP5 expression.

Conclusion: The present data suggest that (99m)Tc-TF uptake is not influenced by glioma's MDR phenotype. Thus, (99m)Tc-TF constitutes a suitable radiotracer for imaging gliomas.

PubMed Disclaimer

References

    1. J Neurooncol. 2005 Sep;74(2):113-21 - PubMed
    1. Q J Nucl Med. 2002 Dec;46(4):336-45 - PubMed
    1. Eur J Cancer. 1993;29A(5):753-9 - PubMed
    1. Clin Neurol Neurosurg. 2008 Jul;110(7):645-8 - PubMed
    1. Cancer Biother Radiopharm. 2005 Jun;20(3):249-59 - PubMed

Substances

LinkOut - more resources